The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 26, 2020

Filed:

Mar. 21, 2017
Applicant:

Council of Scientific & Industrial Research, New Delhi, IN;

Inventors:

Arindam Talukdar, Jadavpur, IN;

Dipyaman Ganguly, Jadavpur, IN;

Barnali Paul, Jadavpur, IN;

Ayan Mukherjee, Jadavpur, IN;

Shounak Roy, Jadavpur, IN;

Swarnali Roy, Jadavpur, IN;

Amrit Raj Ghosh, Jadavpur, IN;

Roopkatha Bhattacharya, Jadavpur, IN;

Oindrila Rahaman, Jadavpur, IN;

Biswajit Kundu, Jadavpur, IN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 239/95 (2006.01); A61P 37/04 (2006.01); C07D 403/14 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61P 37/04 (2018.01); C07D 239/95 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01);
Abstract

The present invention relates to small molecule 4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defense for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.


Find Patent Forward Citations

Loading…